Navigation Links
OncoGenex Reports Second Quarter Financial Results
Date:8/5/2010

with advanced prostate cancer, many patients will eventually develop treatment resistance and their disease will progress."

Cormack added, "Our partnership with Teva Pharmaceuticals has financed a robust clinical trial program for custirsen and provided us with the cash to fund operations into mid-2012, while retaining royalty rates which we estimate at the higher tiers could approach economics seen in profit-sharing arrangements. We're now focusing on advancing OGX-427 to more fully realize its diverse potential. We are currently evaluating various alternatives, including partnering, which would allow us to expand the OGX-427 development plan beyond the ongoing Phase 1 bladder cancer trial and the randomized Phase 2 prostate cancer trial planned to initiate later this year."

Recent Accomplishments and Anticipated Milestones

    Custirsen
    ---------

      -  In partnership with Teva, we initiated the international Phase 3
         Prostate Cancer SATURN trial evaluating custirsen with docetaxel
         retreatment as second-line therapy in castrate-resistant prostate
         cancer (CRPC). The SATURN trial will be conducted in approximately
         50 cancer centers and will enroll approximately 300 men who have
         previously responded to first-line docetaxel therapy, but
         subsequently have disease progression that involves prostate cancer-
         related pain despite opioid usage.

      -  Two additional Phase 3 trials will be initiated evaluating custirsen
         in first-line treatment of metastatic CRPC and first-line treatment
         of advanced, unresectable non-small cell lung cancer (NSCLC). Both
         trials will be in combination with chemotherapy and will assess
         overall survival as the primary endpoint.

    OGX-427
    -------

      -  Final results from a Phase 1 trial of OGX-427 were announced at the
         ASCO 2010 Annual Meetin
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
3. OncoGenex Reports First Quarter Financial Results
4. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
5. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
6. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
7. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
8. OncoGenex Reports Third Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
11. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 WriteResult, a premier provider ... from Yale University’s School of Public Health and New ... during a 4 month-long project. The goal of the ... income families with free access to fresh produce and ... health concerns like high blood pressure, diabetes and weight ...
(Date:3/25/2015)... Agnition announced today that it will ... airing for the first time at 7:30 a.m. CST ... will explore the extremely important role soil microbes perform ... patented Microbial Catalyst™ technology that enhances soil and plant ... will air again on April 28. , A biochemist ...
(Date:3/25/2015)... ROCKVILLE, Md. , March 25, 2015 ... for the Vaccine Industry Excellence (ViE) Award "Best Clinical ... second consecutive year that Optimal has been selected as ... World Vaccine Congress, receiving a "Highly Recommended" distinction in ... generate recognition of the efforts, accomplishments, and positive contributions ...
(Date:3/25/2015)... 2015  S&P Capital IQ (MHFI) announced today ... coverage on Abattis Bioceuticals Corp . ... a specialty biotechnology company with capabilities through its ... proprietary ingredients, bio-similar compounds, patented equipment and consulting ... America . The company seeks to capitalize ...
Breaking Biology Technology:Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... , , DURHAM, N.C., Sept. ... the company,s proxy, which is being mailed today, asks shareholders to ... Oct. 19, 2009. , , "At last years, ... the counter on the bulletin board and we promised to seek ...
... , , , ... of world leader in hyperbaric medicine ... William I. Preuit to the position of senior vice president of ... leading marketing professional such as Bill to this position shows the ...
... TAI,AN, China, Sept. 9 /PRNewswire-Asia-FirstCall/ -- ... ("China Biologic," or the "Company"),one of the ... of China ("PRC"), operating through its indirect ... ("Taibang") and,Chongqing Dalin Biologic Technologies Co., Ltd. ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split 2Sechrist Increases Focus on International Markets; Appoints William Preuit Senior Vice President 2China Biologic Products Appoints Director of Research and Development 2China Biologic Products Appoints Director of Research and Development 3
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... Latin America . Annual estimates and ...
(Date:3/17/2015)... SAN DIEGO , March 17, 2015 /PRNewswire/ ... and emotion analytics software, today announced general availability ... on-demand web service for the analysis of facial ... they experience advertising, media content, products and services. ... customer attention, engagement and sentiment - as derived ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... part, responsible for our higher rates of cancer? That,s a ... Tech,s School of Biology and chief research scientist at the ... study, it seems that McDonald is on to something. The ... Hypothesis and will appear in the forthcoming issue of ...
... PROVIDENCE, R.I. [Brown University] BrainGate, an investigational technology ... people with paralysis to use those signals to control ... clinical trial. The system is based on neuroscience, engineering ... BrainGate2 pilot clinical trial is taking place at Massachusetts ...
... Caribbean have been comprehensively ,flattened, over the last 40 years, ... East Anglia (UEA). The collapse of reef structure has ... whammy for fragile coastal communities in the region. ... was in decline, but this is the first large scale ...
Cached Biology News:Brain-computer interface, developed at Brown, begins new clinical trial 2Brain-computer interface, developed at Brown, begins new clinical trial 3Brain-computer interface, developed at Brown, begins new clinical trial 4Caribbean coral reefs flattened 2
... Sophions newly introduced QPatch HT is taking automated ... powerful level. With its ability to generate thousands ... is enabling new screening paradigms in ion channel ... with the same high quality afforded by conventional ...
... designed for DNA aptamer screening and binding ... powerful Paraflo microfluidic on-chip synthesis platform. These ... comprehensive DNA/RNA Aptamer Microarray Service. ... Microarray contains greater than 1500 known aptamer ...
... a comprehensive epitope analysis service utilizing ... Paraflo microfluidic chips for immunological studies, ... comprehensive service includes assistance with your ... provided by you, single or dual ...
... commonly used as a fusion partner when ... GSTTag sequence has been reported to enhance ... solubility of its fusion partners. When expressed ... fusion proteins can be purified with immobilized ...
Biology Products: